Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Meningococcal B Vaccines in Asplenic Patients
NCT04166656Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2022
- Primary completion
- Sep 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meningococcal group B vaccine in meningococcal group B infection (MenB) (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Proportion of responders defined as participants with seroconversion at Month 7. Started Sep 2022; status: recruiting.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal group B infection (MenB)
Beyond the preview
Go deeper on NCT04166656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04166656.